MUC1 glycopeptide epitopes predicted by computational glycomics.

Area of Science:

• Glycobiology and glycomics
• Cancer research
• Immunology

Background:

• Bioinformatic tools are crucial for glycobiology and glycomics, but empirical validation of computational findings is emerging.
• MUC1, a cancer-associated mucin, exhibits aberrant glycosylation in tumors, yet the specific glyco-epitopes driving immune responses remain unclear.
• Existing research on MUC1 glycopeptides uses synthetic antigens, not authentic tumor-expressed epitopes.

Purpose of the Study:

• To predict MUC1 glycan epitopes using computational glycomics.
• To examine the in vivo immunogenicity of authentic MUC1 glyco-epitopes expressed by cancer cells.
• To develop tools for cancer glycan and peptide sequence research, diagnosis, and therapy.

Main Methods:

• Computational glycomics was used to predict MUC1 glycan epitopes.
• Membrane-bound MUC1 tandem repeats were expressed in a glycosylation-deficient cell line (Jurkat).
• Mice were immunized with cancer cells expressing authentic MUC1 glyco-epitopes, and antibody responses were analyzed using chemically synthesized glycopeptides and ELISA.

Main Results:

• Antibody responses to specific MUC1 glyco-epitopes were characterized.
• A monoclonal antibody (16A) demonstrated significantly higher binding affinity to a glycosylated MUC1 peptide compared to its non-glycosylated form (25-fold difference).
• Chemically synthesized MUC1 glycopeptides enabled antibody generation and characterization.

Conclusions:

• Authentic MUC1 glyco-epitopes expressed by cancer cells can elicit specific antibody responses.
• A library of monoclonal antibodies targeting MUC1 glycopeptides can serve as valuable tools for cancer research.
• These antibodies hold potential as diagnostic and therapeutic reagents for cancer treatment.